Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral drug
Fierce Biotech
Study finds HIV can evolve to resist lenacapavir—at a cost
After exposure to lenacapavir, HIV was able to shift the structure of its protein coating to avoid the drug’s effects.
Darren Incorvaia
Jan 7, 2026 2:00pm
Shionogi's antiviral comes up short in global COVID-19 trial
May 13, 2024 10:48am
Pfizer's Paxlovid access questioned ahead of WTO patent talks
Nov 21, 2022 11:41am
FDA swats away Gilead's hepatitis D treatment bulevirtide
Oct 28, 2022 9:52am
Gilead plots pivotal clinical trial for COVID oral antiviral
Oct 19, 2022 12:01am
Pfizer stops Paxlovid work in less vulnerable COVID patients
Jun 15, 2022 10:20am
